Finch Therapeutics Group, Inc. (FNCH)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Finch Therapeutics Group, Inc. (FNCH) with AI Score 38/100 (Weak). Finch Therapeutics Group, Inc. is a clinical-stage biotechnology company focused on developing microbiome therapeutics. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026Finch Therapeutics Group, Inc. (FNCH) Healthcare & Pipeline Overview
Finch Therapeutics Group, Inc. is a clinical-stage microbiome therapeutics company developing orally administered biological drugs. Their lead candidate, CP101, addresses recurrent Clostridioides difficile infection. The company collaborates with Takeda Pharmaceutical and others, positioning it within the evolving microbiome-based therapeutics landscape and offering potential for growth in treating unmet medical needs.
Investment Thesis
Finch Therapeutics presents a high-risk, high-reward investment opportunity within the microbiome therapeutics space. The company's lead candidate, CP101, targeting recurrent Clostridioides difficile infection (CDI), is in Phase 3 trials, representing a near-term value driver if successful. Positive clinical trial data for CP101 could significantly boost investor confidence. Furthermore, the development of FIN-211 for autism spectrum disorder and TAK-524/FIN-525 for ulcerative colitis and Crohn's disease provides longer-term growth potential. However, the company's small market capitalization ($0.02B) and limited number of employees (1) indicate substantial operational and financial risks. Dependence on collaborations and licensing agreements also introduces external dependencies. The negative P/E ratio (-1.48) reflects current unprofitability, highlighting the need for successful clinical trials and subsequent commercialization to drive shareholder value.
Based on FMP financials and quantitative analysis
Key Highlights
- CP101 is in Phase 3 clinical trials for recurrent Clostridioides difficile infection, representing a potential near-term catalyst.
- Developing FIN-211 for autism spectrum disorder expands the therapeutic pipeline.
- Collaborations with Takeda Pharmaceutical, Skysong Innovations LLC, and University of Minnesota provide external validation and resources.
- Market capitalization of $0.02B indicates a small-cap company with high growth potential but also significant risk.
- Negative P/E ratio of -1.48 reflects current unprofitability and reliance on future clinical and commercial success.
Competitors & Peers
Strengths
- Novel microbiome therapeutic platform.
- Lead candidate CP101 in Phase 3 clinical trials.
- Strategic collaborations with Takeda and other institutions.
- Focus on unmet medical needs.
Weaknesses
- Small market capitalization and limited employees.
- Reliance on clinical trial success.
- Dependence on collaborations and licensing agreements.
- Negative P/E ratio indicates current unprofitability.
Catalysts
- Upcoming: Phase 3 clinical trial results for CP101 in recurrent Clostridioides difficile infection.
- Upcoming: Potential regulatory approval and commercial launch of CP101.
- Ongoing: Development of FIN-211 for autism spectrum disorder.
- Ongoing: Advancement of TAK-524 and FIN-525 for ulcerative colitis and Crohn's disease.
- Ongoing: Strategic partnerships and collaborations.
Risks
- Potential: Clinical trial failures for CP101 or other pipeline candidates.
- Potential: Regulatory hurdles and delays in obtaining approvals.
- Ongoing: Competition from other biotechnology companies.
- Ongoing: Financial constraints and need for additional funding.
- Ongoing: Risks associated with trading on the OTC market.
Growth Opportunities
- CP101 Commercialization: Successful completion of Phase 3 trials and subsequent commercialization of CP101 for recurrent Clostridioides difficile infection (CDI) represents a significant growth opportunity. The market for CDI treatment is substantial, with a growing incidence of infection. A successful product launch could generate significant revenue for Finch. Timeline: Potential launch within 1-2 years following positive trial results and regulatory approval.
- Expansion into Chronic Hepatitis B Virus (HBV): CP101 is also being explored as a treatment for chronic hepatitis B virus (HBV). If successful, this could significantly expand the market opportunity for CP101. The global market for HBV treatment is substantial, driven by the large number of individuals infected with HBV. Timeline: Clinical trials and potential commercialization within 3-5 years.
- Development of FIN-211 for Autism Spectrum Disorder (ASD): The development of FIN-211, an orally administered enriched consortia product candidate for autism spectrum disorder (ASD), represents a novel approach to treating this complex condition. The market for ASD treatments is growing, driven by increasing awareness and diagnosis. Timeline: Clinical trials and potential commercialization within 5-7 years.
- Advancement of TAK-524 and FIN-525 for Ulcerative Colitis and Crohn's Disease: The development of TAK-524 and FIN-525, orally administered targeted consortia product candidates for ulcerative colitis and Crohn's disease, addresses a significant unmet need in inflammatory bowel disease (IBD). The market for IBD treatments is substantial and growing. Timeline: Clinical trials and potential commercialization within 5-7 years.
- Strategic Partnerships and Collaborations: Finch's existing collaborations with Takeda Pharmaceutical Company Limited, Skysong Innovations LLC, and the University of Minnesota provide access to resources and expertise. Further strategic partnerships could accelerate the development and commercialization of its microbiome therapeutics. Timeline: Ongoing, with potential for new partnerships in the near to medium term.
Opportunities
- Successful commercialization of CP101.
- Expansion into new therapeutic areas (HBV, ASD, IBD).
- Further strategic partnerships and collaborations.
- Growing market for microbiome-based therapies.
Threats
- Clinical trial failures.
- Regulatory hurdles.
- Competition from other biotechnology companies.
- Financial constraints and need for additional funding.
Competitive Advantages
- Proprietary microbiome therapeutic platform.
- Clinical-stage pipeline of product candidates.
- Strategic collaborations with leading pharmaceutical companies and research institutions.
- Intellectual property protection for its microbiome therapeutics.
About FNCH
Finch Therapeutics Group, Inc., founded in 2014 and based in Somerville, Massachusetts, is a clinical-stage biotechnology company pioneering a novel class of orally administered microbiome therapeutics. The company is dedicated to harnessing the power of the microbiome to treat a range of diseases with unmet medical needs. Finch's lead candidate, CP101, is an orally administered microbiome capsule currently in Phase 3 clinical trials for the treatment of recurrent Clostridioides difficile infection (CDI). CP101 is also being explored as a potential treatment for chronic hepatitis B virus (HBV). Beyond CP101, Finch is developing a pipeline of additional microbiome therapeutics, including FIN-211, an orally administered enriched consortia product candidate for autism spectrum disorder (ASD), and TAK-524 and FIN-525, which are orally administered targeted consortia product candidates for ulcerative colitis and Crohn's disease. Finch has established collaborations and license agreements with Takeda Pharmaceutical Company Limited, Skysong Innovations LLC, and the University of Minnesota, reflecting a commitment to strategic partnerships to advance its research and development efforts. While the company currently has a small number of employees, its focus on innovative microbiome therapies positions it within a rapidly evolving field with significant potential.
What They Do
- Develop orally administered microbiome therapeutics.
- Focus on treating diseases with unmet medical needs.
- Lead candidate CP101 targets recurrent Clostridioides difficile infection.
- Developing FIN-211 for autism spectrum disorder.
- Developing TAK-524 and FIN-525 for ulcerative colitis and Crohn's disease.
- Collaborate with pharmaceutical companies and research institutions.
Business Model
- Develop and commercialize microbiome-based therapeutics.
- Generate revenue through product sales and licensing agreements.
- Collaborate with pharmaceutical companies for research and development.
Industry Context
Finch Therapeutics operates within the rapidly evolving microbiome therapeutics industry. This sector is characterized by increasing scientific understanding of the role of the microbiome in human health and disease. The market for microbiome-based therapies is projected to grow significantly, driven by the potential to address unmet needs in various diseases. Finch faces competition from other biotechnology companies developing microbiome-based products, including BBIXF (BetterLife Pharma Inc.), CLYYF (Calyxt Inc.), CWBHF (Cannabics Pharmaceuticals Inc.), ELVAF (Eleva Labs SA), and MEDIF (Medifast Inc.). Success in this field requires strong scientific expertise, successful clinical trials, and effective commercialization strategies.
Key Customers
- Patients with recurrent Clostridioides difficile infection.
- Patients with autism spectrum disorder.
- Patients with ulcerative colitis and Crohn's disease.
- Pharmaceutical companies through collaborations and licensing.
Financials
Chart & Info
Finch Therapeutics Group, Inc. (FNCH) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Lows On Monday
benzinga · Aug 14, 2023
-
Stocks That Hit 52-Week Lows On Wednesday
benzinga · Nov 16, 2022
-
Stocks That Hit 52-Week Lows On Friday
benzinga · Oct 21, 2022
-
Stocks That Hit 52-Week Lows On Thursday
benzinga · Apr 28, 2022
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for FNCH.
Price Targets
Wall Street price target analysis for FNCH.
MoonshotScore
What does this score mean?
The MoonshotScore rates FNCH's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Matthew Blischak
CEO
Matthew Blischak currently serves as the CEO of Finch Therapeutics Group, Inc. His background includes experience in managing and leading companies, though specific details on his prior roles and educational background are not provided in the source data. As CEO, he is responsible for the overall strategic direction and operational execution of the company's microbiome therapeutics programs.
Track Record: Given the limited information available, it's difficult to assess Matthew Blischak's specific track record at Finch Therapeutics. However, as CEO, he is overseeing the clinical development of CP101 and other pipeline candidates, as well as managing collaborations with Takeda and other partners. The success of these initiatives will be key to evaluating his leadership.
FNCH OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Finch Therapeutics Group, Inc. may not meet the minimum financial or reporting requirements of higher tiers like OTCQX or OTCQB. Companies on the OTC Other tier may have limited financial disclosure, be undergoing restructuring, or face regulatory issues. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies are not subject to the same stringent listing standards, potentially increasing investment risk.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Lower trading volume and liquidity.
- Increased price volatility.
- Potential for fraud or manipulation.
- Higher risk of delisting or going out of business.
- Verify the company's financial statements and disclosures.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's legal and regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Confirm the legitimacy of the stock and trading platform.
- Existing collaborations with reputable pharmaceutical companies (e.g., Takeda).
- Clinical-stage pipeline with ongoing trials.
- Focus on addressing unmet medical needs.
- Incorporation in 2014 suggests some operating history.
- Headquarters located in Somerville, Massachusetts.
What Investors Ask About Finch Therapeutics Group, Inc. (FNCH)
What does Finch Therapeutics Group, Inc. do?
Finch Therapeutics Group, Inc. is a clinical-stage biotechnology company focused on developing a novel class of orally administered microbiome therapeutics. Their lead candidate, CP101, is in Phase 3 clinical trials for the treatment of recurrent Clostridioides difficile infection (CDI) and is also being explored for chronic hepatitis B virus (HBV). Additionally, Finch is developing other product candidates, including FIN-211 for autism spectrum disorder (ASD) and TAK-524/FIN-525 for ulcerative colitis and Crohn's disease, aiming to address unmet medical needs through innovative microbiome-based therapies.
What do analysts say about FNCH stock?
AI analysis is currently pending for FNCH, and therefore, there is no available analyst consensus, valuation metrics, or growth considerations. Given the company's clinical-stage nature and focus on microbiome therapeutics, potential investors should closely monitor clinical trial results, regulatory developments, and financial performance to assess the investment opportunity. The company's success hinges on the successful development and commercialization of its product candidates.
What are the main risks for FNCH?
Finch Therapeutics faces several key risks, including the potential for clinical trial failures, regulatory hurdles, and competition from other biotechnology companies. The company's small market capitalization and limited number of employees also present operational and financial risks. Furthermore, as an OTC-listed company, Finch is subject to increased volatility and liquidity risks. The company's reliance on collaborations and licensing agreements introduces external dependencies that could impact its development and commercialization efforts. The negative P/E ratio reflects current unprofitability and reliance on future clinical and commercial success.
What are the key factors to evaluate for FNCH?
Finch Therapeutics Group, Inc. (FNCH) currently holds an AI score of 38/100, indicating low score. Key strength: Novel microbiome therapeutic platform.. Primary risk to monitor: Potential: Clinical trial failures for CP101 or other pipeline candidates.. This is not financial advice.
How frequently does FNCH data refresh on this page?
FNCH prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven FNCH's recent stock price performance?
Recent price movement in Finch Therapeutics Group, Inc. (FNCH) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Novel microbiome therapeutic platform.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider FNCH overvalued or undervalued right now?
Determining whether Finch Therapeutics Group, Inc. (FNCH) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying FNCH?
Before investing in Finch Therapeutics Group, Inc. (FNCH), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on CEO track record.
- AI analysis pending for FNCH.
- OTC market investments are highly speculative.